Modeling Pharmaceutical Powder-Flow Performance Using Particle-Size Distribution Data - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Modeling Pharmaceutical Powder-Flow Performance Using Particle-Size Distribution Data
The authors present a simple and material-sparing approach for estimating the powder-flow performance of previously uncharacterized single-component bulk powders when only particle-size distribution data are available.


Pharmaceutical Technology
Volume 33, Issue 3, pp. 126-134

Conclusion

Models have been developed for predicting relative powder-flow performance using PSD data. The PLS model, which used D10, D50, D90, and D[4,3] as input parameters, is suitable for predicting the FFC value for APIs and excipients and may also be appropriate for predicting PSD influences on other materials (e.g., active blends and active granulations). This empirical tool leverages a material and resource-sparing approach to the powder-flow performance characterization. In addition, the tool can be particularly useful during prototype drug-product design, especially with regard to risk assessments when little is known about the flow performance of a new API or excipient.

Acknowledgment

The authors would like to thank Bruno Hancock for reviewing this work and providing technical guidance.

Matthew P. Mullarney* and Norma Leyva are senior scientists at Pfizer, Inc., Eastern Point Rd., Groton, CT 06340, tel. 860.715.4139,
.

*To whom all correspondence should be addressed.

Submitted: June 16, 2008. Accepted: July 8, 2008.




What would you do differently? Submit your comments about this paper in the space below.

References

1. E.N. Hiestand, "Mechanics and Physical Principles for Powders and Compacts" (SSCI Inc., West Lafayette, IN, 2002), p 110.

2. J. Staniforth, "Powder Flow," in Pharmaceutics: The Science of Dosage Form Design, M.E. Aulton, Ed. (Churchill Livingstone, Edinburgh, UK, 2002) pp. 197–210.

3. G.E. Amidon and M.E. Houghton, "Powder Flow Testing in Preformulation and Formulation Development," Pharma. Manuf., 2 (7) 21–31 (1985).

4. A.W. Jenike, "Storage and Flow of Solids," in Utah Engineering Experiment Station Bulletin 123, 16th ed., (University of Utah, Salt Lake City, UT, 1964).

5. T. Kohler and H. Schubert, "Influence of Particle Size Distribution on the Flow Behavior of Fine Powders," Part. Syst. Charact. 8 (1–4), 101–104 (1991).

6. F. Podczeck and Y. Miah, "The Influence of Particle Size and Shape on the Angle of Internal Friction and the Flow Factor of Unlubricated and Lubricated Powders," Int. J. Pharm. 144 (2) 187–194 (1996).

7. L. Breiman et al., "Classification and Regression Trees" (Chapman & Hall/CRC, Boca Raton, FL, 1984).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology,
Click here